Drug Sales Trends for ENDOMETRIN

Annual Sales Revenues and Units Sold for ENDOMETRIN

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
ENDOMETRIN			2021
ENDOMETRIN			2020
ENDOMETRIN			2019
ENDOMETRIN			2018
ENDOMETRIN			2017
ENDOMETRIN			2016
ENDOMETRIN			2015

Endometriosis Market Analysis and Sales Projections: A Comprehensive Overview

Introduction

Endometriosis, a chronic and often debilitating condition affecting millions of women worldwide, has seen significant advancements in treatment options over the past few years. This article delves into the market analysis and sales projections for the endometriosis treatment market, with a focus on key drivers, segments, and regional insights.

Market Size and Growth Projections

The global endometriosis treatment market is poised for substantial growth. As of 2020, the market size across the seven major markets (7MM: US, 5EU, and Japan) was valued at $1.05 billion. It is projected to grow at a compound annual growth rate (CAGR) of around 10% to reach $2.72 billion by 2030[1][3].

Key Drivers of Market Growth

Several factors are driving the growth of the endometriosis treatment market:

New Drug Launches

The market release of several gonadotropin-releasing hormone (GnRH) receptor antagonists, such as Myovant’s Myfembree (relugolix, estradiol, and norethindrone acetate) and Kissei Pharmaceutical’s Yselty (linzagolix), is a significant driver. These drugs have shown promising results in managing endometriosis-associated pain and are expected to stimulate sales growth[1][2].

Strategic Collaborations

Strategic collaborations among key players are also boosting market growth. For instance, the licensing agreement between ObsEva SA and Theramex to expand linzagolix outside of the U.S., Canada, and Asia is expected to enhance market penetration[2][4].

Increasing Awareness and Healthcare Expenditure

Growing awareness of endometriosis, coupled with increasing healthcare expenditure, is leading to a higher volume of prescriptions for endometriosis drugs. This trend is particularly evident in outpatient settings, where retail pharmacies dominate the distribution channel[2][4].

Market Segmentation

Treatment Type

The endometriosis market is segmented into pain medication and hormone therapy. The pain medication segment currently holds the highest market share, driven by the need to alleviate painful symptoms such as dysmenorrhea and chronic pelvic pain. However, the hormone therapy segment, which includes drugs like AbbVie’s Orilissa (elagolix), is expected to witness a CAGR of 13.99% during the forecast period[2][4].

Drug Class

Key drug classes include GnRH agonists, progestins, estrogen antagonists, GnRH antagonists, and dopamine D2 receptor antagonists. GnRH agonists accounted for the largest sales share in the US market in 2020, but the uptake of GnRH antagonists is expected to drive future growth[3].

Route of Administration

The oral route of administration dominates the market, accounting for a significant revenue share. This is due to the convenience and effectiveness of oral medications such as NSAIDs, oral contraceptives, and oral GnRH agonists. Novel treatments like transdermal drug delivery technologies are also gaining traction[2][4].

Distribution Channel

Retail pharmacies hold the largest revenue share, with 67.4% of the market in 2023. This is attributed to the high presence of over-the-counter drugs and the fact that most endometriosis patients are treated in outpatient settings. Hospital pharmacies are expected to experience moderate growth due to the rising preference for surgical treatments in hospital settings[2][4].

Regional Insights

North America

North America, particularly the US, dominates the endometriosis market and is expected to maintain its dominance. The US will contribute approximately 81.3% of the 7MM sales by 2030. This is due to the higher diagnosed prevalence of endometriosis and the higher prices of drugs in the US compared to other regions[1][4].

Europe and Asia-Pacific

The 5EU region (France, Germany, Italy, Spain, and the UK) and Japan also play significant roles, with the launch of new drugs like Myfembree and Yselty expected to drive growth. The Asia-Pacific region is anticipated to experience the highest growth rate, driven by increasing endometriosis cases and growing purchasing power in countries like China and India[1][4].

Competitive Landscape

The endometriosis market is moderately competitive, with leading companies such as AbbVie, Bayer, Evotec, Kissei Pharmaceuticals, and Pfizer holding a majority share. New entrants and strategic initiatives like new launches, collaborations, mergers, and acquisitions are expected to make the market increasingly competitive during the forecast period[2][4].

Key Takeaways

• The global endometriosis treatment market is projected to grow significantly, driven by new drug launches and strategic collaborations.
• The hormone therapy segment, particularly GnRH antagonists, is expected to witness high growth.
• Retail pharmacies dominate the distribution channel, while the oral route of administration remains the most common.
• North America, especially the US, will continue to be the largest market for endometriosis treatments.
• The Asia-Pacific region is expected to experience the highest growth rate due to increasing endometriosis cases and growing healthcare expenditure.

FAQs

Q: What is the projected CAGR for the endometriosis treatment market from 2020 to 2030? A: The market is expected to grow at a CAGR of around 10% from 2020 to 2030[1][3].

Q: Which drug classes are expected to drive market growth in the endometriosis treatment market? A: GnRH antagonists, such as Myfembree and Yselty, are expected to drive significant growth in the market[1][2].

Q: What is the dominant distribution channel for endometriosis treatments? A: Retail pharmacies dominate the distribution channel, accounting for 67.4% of the market share in 2023[2][4].

Q: Which region is expected to contribute the most to the endometriosis market by 2030? A: The US is expected to contribute approximately 81.3% of the 7MM sales by 2030[1].

Q: What are the key factors driving the growth of the endometriosis treatment market? A: Key factors include new drug launches, strategic collaborations, increasing awareness of the disease, and rising healthcare expenditure[1][2][4].

Sources

1. Pharmaceutical Technology: "Endometriosis market projected to grow at a CAGR of 10% between 2020 and 2030"[1].
2. Grand View Research: "Endometriosis Treatment Market Size & Trends Report, 2030"[2].
3. GlobalData: "Endometriosis Market Size, Trend Report, Clinical Trial Strategies"[3].
4. Maximize Market Research: "Endometriosis Market- Global Industry Analysis and Forecast"[4].